Search

Your search keyword '"Cannavò MR"' showing total 4 results
Start Over Author "Cannavò MR"
4 results on '"Cannavò MR"'

2. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study

Author

Cabibbo, G., Petta, S., Calvaruso, V., Cacciola, Irene, Cannavã², M. R., Madonia, Simona, Distefano, M., Larocca, L., Prestileo, T., Tinã, F., Bertino, G., Giannitrapani, L., Benanti, F., Licata, Aurelio, Scalisi, I., Mazzola, G., Cartabellotta, F., Alessi, Nunziata, Barbã ra, M., Russello, M., Scifo, G., Squadrito, G., Raimondo, G., Craxã¬, A., Di Marco, V., Cammãundefined, C., Colletti, P., Corrao, S., Di Lorenzo, F., Fecarotta, R., Sanfilippo, Paola, Malizia, G., Latteri, F., Maida, M., Vassallo, R., Cacciola, I., Caccamo, G., Maimone, Sergio, Saitta, C., Mondello, Luigi, Smedile, A., Ardiri, A. L., Montineri, A., Larocca, L. N., Cacopardo, B., Benigno, Rosalia, Bellia, A., Iacobello, C., Davã¬, A., Di Rosolini, M. A., Digiacomo, A., Fuduli, G., Portelli, V., Savalli, F., Scalici, I., Gioia, Giulia, Magro, A., Alaimo, Grazia, Salvo, A., Averna, A., Lomonaco, F., Quattrocchi, U., Guarneri, L., Maffeo, F., Cabibbo, G., Petta, S., Calvaruso, V., Cacciola, I., Cannavò, MR., Madonia, S., Distefano, M., Larocca, L., Prestileo, T., Tinè, F., Bertino, G., Giannitrapani, L., Benanti, F., Licata, A., Scalisi, I., Mazzola, G., Cartabellotta, F., Alessi, N., Barbarà, M., Russello, M., Scifo, G., Squadrito, G., Raimondo, G., Craxã¬, A., DI MARCO, V., Cammà, C., Colletti, P., Corrao, S., Di Lorenzo, F., Fecarotta, R., Sanfilippo, P., Tinã, F., Malizia, G., Latteri, F., Maida, M., Vassallo, R., Caccamo, G., Maimone, S., Saitta, C., Mondello, L., Smedile, A., Ardiri, A., Montineri, A., Cacopardo, B., Benigno, R., Cannavã², M., Bellia, A., Iacobello, C., Davã¬, A., Di Rosolini, M., Digiacomo, A., Fuduli, G., Portelli, V., Savalli, F., Scalici, I., Gioia, G., Magro, A., Alaimo, G., Salvo, A., Averna, A., Lomonaco, F., Quattrocchi, U., Guarneri, L., and Maffeo, F.

Subjects
Liver Cirrhosis, Male, medicine.medical_specialty, Carcinoma, Hepatocellular, Settore MED/09 - Medicina Interna, Early Recurrence, DIRECT ACTING ANTIVIRALS, Antiviral Agents, Gastroenterology, hepatocellular carcinoma (HCC), 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, medicine, Clinical endpoint, Carcinoma, Humans, Pharmacology (medical), Prospective Studies, Prospective cohort study, neoplasms, Complete response, Aged, hepatocellular carcinoma (HCC), HCV, directacting antivirals (DAAs), Settore MED/12 - Gastroenterologia, Settore MED/08 - ANATOMIA PATOLOGICA, Hepatology, business.industry, directacting antivirals (DAAs), Liver Neoplasms, Cancer, Hepatocellular, Middle Aged, medicine.disease, Hepatitis C, digestive system diseases, Neoplasm Recurrence, Local, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, HCV, Catheter Ablation, Female, 030211 gastroenterology & hepatology, Neoplasm Recurrence, Local, business
Abstract

SummaryBackground Data on HCV-related hepatocellular carcinoma (HCC) early recurrence in patients whose HCC was previously cured, and subsequently treated by direct-acting antivirals (DAAs), are equivocal. Aim To assess the risk of HCC early recurrence after DAAs exposure in a large prospective cohort of HCV-cirrhotic patients with previous successfully treated HCC, also looking for risk factors for cancer early recurrence. Methods We enrolled 143 consecutive patients with complete response after curative treatment of HCC, subsequently treated with DAAs and monitored by the web-based RESIST-HCV database. Clinical, biological, and virological data were collected. The primary endpoint was the probability of HCC early recurrence from DAA starting by Kaplan-Meier method. Results Eighty-six per cent of patients were in Child-Pugh class A and 76% of patients were BCLC A. Almost all patients (96%) achieved sustained virological response. Twenty-four HCC recurrences were observed, with nodular or infiltrative pattern in 83% and 17% of patients, respectively. The 6-, 12- and 18-month HCC recurrence rates were 12%, 26.6% and 29.1%, respectively. Main tumour size and history of prior HCC recurrence were independent risk factors for HCC recurrence by Cox multivariate model. Conclusions Probability of HCC early recurrence in patients who had HCC previously cured remains high, despite HCV eradication by DAAs. Risk was comparable but not higher to that reported in literature in DAA-untreated patients. Previous HCC recurrence and tumour size can be used to stratify the risk of HCC early recurrence. Further studies are needed to assess impact of DAAs on late recurrence and mortality.

Published
2017

3. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.

Author

Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavò MR, Madonia S, Rossi M, Magro B, Rini F, Distefano M, Larocca L, Prestileo T, Malizia G, Bertino G, Benanti F, Licata A, Scalisi I, Mazzola G, Di Rosolini MA, Alaimo G, Averna A, Cartabellotta F, Alessi N, Guastella S, Russello M, Scifo G, Squadrito G, Raimondo G, Trevisani F, Craxì A, Di Marco V, and Cammà C

Subjects
Aged, Aged, 80 and over, Carcinoma, Hepatocellular surgery, Female, Follow-Up Studies, Hepatitis C virology, Humans, Liver Neoplasms surgery, Male, Middle Aged, Neoplasm Recurrence, Local, Propensity Score, Prospective Studies, Survival Rate, Sustained Virologic Response, Antiviral Agents therapeutic use, Carcinoma, Hepatocellular etiology, Carcinoma, Hepatocellular mortality, Hepacivirus genetics, Hepatitis C complications, Hepatitis C drug therapy, Liver Cirrhosis complications, Liver Neoplasms etiology, Liver Neoplasms mortality
Abstract

Background & Aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation., Methods: We prospectively enrolled 163 consecutive patients with HCV-related cirrhosis and a first diagnosis of early Barcelona Clinic Liver Cancer stage 0/A HCC, who had achieved a complete radiologic response after curative resection or ablation and were subsequently treated with DAAs. DAA-untreated patients from the ITA.LI.CA. cohort (n = 328) served as controls. After propensity score matching, outcomes of 102 DAA-treated (DAA group) and 102 DAA-untreated patients (No DAA group) were compared., Results: In the DAA group, 7/102 patients (6.9%) died, HCC recurred in 28/102 patients (27.5%) and hepatic decompensation occurred in 6/102 patients (5.9%), after a mean follow-up of 21.4 months. OS was significantly higher in the DAA group compared to the No DAA group (hazard ratio [HR] 0.39; 95% CI0.17-0.91; p = 0.03). HCC recurrence was not significantly different between the DAA and No DAA groups (HR0.70; 95% CI0.44-1.13; p = 0.15). A significant reduction in the rate of hepatic decompensation was observed in the DAA group compared with the No DAA group (HR0.32; 95% CI0.13-0.84; p = 0.02). In the DAA group, sustained virologic response was a significant predictor of OS (HR 0.02; 95% CI 0.00-0.19; p <0.001), HCC recurrence (HR 0.25; 95% CI 0.11-0.57; p <0.001) and hepatic decompensation (HR 0.12; 95% CI 0.02-0.38; p = 0.02)., Conclusions: In patients with HCV-related cirrhosis who had been successfully treated for early HCC, DAAs significantly improved OS compared with No DAA treatment., Lay Summary: We aimed to determine whether direct-acting antivirals (DAAs) significantly improve overall survival in patients with hepatitis C virus-related compensated cirrhosis and a first diagnosis of hepatocellular carcinoma (HCC) which has been successfully treated with curative resection or ablation. Using propensity-score matched patients, we found that DAAs improved overall survival and reduced the risk of hepatic decompensation. However, the risk of HCC recurrence was not significantly reduced., (Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.)

Published
2019
Full Text
View/download PDF

4. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.

Author

Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, Madonia S, Distefano M, Larocca L, Prestileo T, Tinè F, Bertino G, Giannitrapani L, Benanti F, Licata A, Scalisi I, Mazzola G, Cartabellotta F, Alessi N, Barbàra M, Russello M, Scifo G, Squadrito G, Raimondo G, Craxì A, Di Marco V, and Cammà C

Subjects
Aged, Carcinoma, Hepatocellular virology, Catheter Ablation, Female, Hepatitis C drug therapy, Humans, Liver Cirrhosis complications, Liver Cirrhosis drug therapy, Liver Neoplasms virology, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Prospective Studies, Risk Factors, Antiviral Agents therapeutic use, Carcinoma, Hepatocellular pathology, Hepatitis C complications, Liver Neoplasms pathology
Abstract

Background: Data on HCV-related hepatocellular carcinoma (HCC) early recurrence in patients whose HCC was previously cured, and subsequently treated by direct-acting antivirals (DAAs), are equivocal., Aim: To assess the risk of HCC early recurrence after DAAs exposure in a large prospective cohort of HCV-cirrhotic patients with previous successfully treated HCC, also looking for risk factors for cancer early recurrence., Methods: We enrolled 143 consecutive patients with complete response after curative treatment of HCC, subsequently treated with DAAs and monitored by the web-based RESIST-HCV database. Clinical, biological, and virological data were collected. The primary endpoint was the probability of HCC early recurrence from DAA starting by Kaplan-Meier method., Results: Eighty-six per cent of patients were in Child-Pugh class A and 76% of patients were BCLC A. Almost all patients (96%) achieved sustained virological response. Twenty-four HCC recurrences were observed, with nodular or infiltrative pattern in 83% and 17% of patients, respectively. The 6-, 12- and 18-month HCC recurrence rates were 12%, 26.6% and 29.1%, respectively. Main tumour size and history of prior HCC recurrence were independent risk factors for HCC recurrence by Cox multivariate model., Conclusions: Probability of HCC early recurrence in patients who had HCC previously cured remains high, despite HCV eradication by DAAs. Risk was comparable but not higher to that reported in literature in DAA-untreated patients. Previous HCC recurrence and tumour size can be used to stratify the risk of HCC early recurrence. Further studies are needed to assess impact of DAAs on late recurrence and mortality., (© 2017 John Wiley & Sons Ltd.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results